Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Lyra Therapeutics, Inc. (LYRA) had Weighted-Average Shares Outstanding (Diluted) of 1.55M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.40M |
|
$-28.92M |
|
-- |
|
$0.40M |
|
$31.42M |
|
$-31.02M |
|
$2.11M |
|
$-28.91M |
|
$-28.91M |
|
$-28.92M |
|
$-28.92M |
|
$-28.92M |
|
$-28.92M |
|
$-31.02M |
|
$-30.56M |
|
1.55M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
1.55M |
$-18.62 |
|
$-18.62 |
|
| Balance Sheet Financials | |
$16.27M |
|
$1.05M |
|
$19.84M |
|
$36.11M |
|
$9.52M |
|
-- |
|
$37.30M |
|
$46.83M |
|
$-10.72M |
|
$-10.72M |
|
$-10.72M |
|
1.77M |
|
| Cash Flow Statement Financials | |
$-28.86M |
|
$-0.10M |
|
$4.27M |
|
$42.57M |
|
$17.89M |
|
$-24.68M |
|
$2.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.71 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-7794.47% |
|
-7794.47% |
|
-7679.15% |
|
-7263.32% |
|
-7266.08% |
|
$-28.96M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
269.84% |
|
269.84% |
|
-80.09% |
|
269.84% |
|
$-6.04 |
|
$-18.65 |
|
$-18.58 |
|